Bidirectional communication between tumours and neurons has emerged as a key facet of the tumour microenvironment that drives malignancy1,2. Another hallmark feature of cancer is epigenomic dysregulation, in which alterations in gene expression influence cell states and interactions with …
A combination of immunological reaction to a drug and HHV-6 reactivation results in the severe course of DIHS. The demonstration of HHV-6 reactivation is a…
Multiple myeloma disproportionately affects Black Americans, who are twice as likely to be diagnosed with it and its precursor, monoclonal gammopathy of undetermined significance (MGUS).…
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
Below are videos of three women entrepreneurs being interviewed by Jim Pulcrano, Professor at IMD
Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.
In this issue of Blood Advances, Badawy et al1 address the issue of neutropenia and its associated long-term infection risks in a large cohort of patients
Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.
Despite aging being one of the strongest risk factors for cancer, little is known about the biological mechanisms that promote tumor initiation. In this issue…
Chimeric antigen receptor-T cell (CAR-T) therapy has transformed the management of refractory hematological malignancies. Now that targeting pathogenic cells of interest with antigen-directed cytotoxic T…
The NCCN recently updated guidelines for genetic testing in breast, ovarian, pancreatic, prostate, colorectal, endometrial, and gastric cancers.
